Clascoterone as a novel treatment for androgenetic alopecia
October 2020
in “Clinical and Experimental Dermatology”

TLDR
Clascoterone may be a promising treatment for hair loss.
The authors propose that clascoterone, a novel androgen receptor inhibitor, may be a promising treatment for androgenetic alopecia. Clascoterone antagonizes dihydrotestosterone (DHT) through competitive binding with cytoplasmic androgen receptors, and DHT is known to play a causal role in the development of androgenetic alopecia. Clascoterone has been found to have the same efficacy as finasteride in vitro and preliminary industry studies demonstrate a hair growth signal comparable with established treatments such as minoxidil. The authors suggest that clascoterone presents a promising therapeutic avenue for this commonly encountered condition.
View this study on academic.oup.com →
Cited in this study

research A summary of in vitro, phase I, and phase II studies evaluating the mechanism of action, safety, and efficacy of clascoterone (cortexolone 17a propionate, CB-03-01) in androgenetic alopecia
Clascoterone safely promotes hair growth similar to minoxidil.

research Efficacy and Safety of Finasteride Therapy for Androgenetic Alopecia
Finasteride helps hair growth but may cause sexual side effects.